trending Market Intelligence /marketintelligence/en/news-insights/trending/xWxRXn02dh5RYpAt0XUR5w2 content esgSubNav
In This List

Xynomic's abexinostat gets US FDA fast-track tag for follicular lymphoma

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Xynomic's abexinostat gets US FDA fast-track tag for follicular lymphoma

Xynomic Pharmaceuticals Holdings Inc.'s abexinostat received the U.S. Food and Drug Administration's fast-track status to treat follicular lymphoma that has returned or is resistant to treatment.

SNL Image

The Cheyenne, Wyo.-based biotechnology company is studying the medicine as a fourth-line treatment of relapsed or refractory follicular lymphoma, a cancer of white blood cells responsible for fighting infections.

The cancer affects about 14,840 people each year in the U.S. and often requires multiple lines of treatment. The disease usually returns less than one year after a patient receives their third line of treatment.

The FDA previously granted fast-track designation to a combination of abexinostat and pazopanib as a first- or second-line treatment of kidney cancer.